Internal Medicine, Nephrology · New York, NY
NPI
1629018908
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
222 E 41st St
New York, NY, 10017
Phone (212) 263-5851
Groups this clinician bills Medicare through
Medicare paid, 2024
$8,281
98 services
Medicare patients, 2024
68
Average age 73
Drug cost, 2024
$410K
565 prescriptions
Company payments, 2025
$6,393
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David S Goldfarb was code 99213 (office e&m - established), 39 times for 36 patients. In total David S Goldfarb billed 98 services in 8 codes, and Medicare paid $8,281.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 39 | 36 | $73.31 | $2,859 |
| 99214 Office E&M - Established | Office | 22 | 20 | $109.09 | $2,400 |
| 81002 Clinical Chemistry | Office | 14 | 14 | $3.41 | $47.74 |
By year: 2022 $9,242 for 91 services; 2023 $7,893 for 96 services; 2024 $8,281 for 98 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 14 | 14 | $3.41 | $47.74 |
Medicare prescription drug claims, 2024
In 2024, the drug David S Goldfarb prescribed most often to Medicare patients was Potassium Citrate Er (Potassium Citrate), with 199 prescriptions and refills. In total David S Goldfarb wrote 565 Medicare prescriptions that cost $410K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Potassium Citrate Er Potassium Citrate | 199 | 462 | 57 | $36K |
| Indapamide Generic | 41 | 83 | Under 11 | $690 |
| Chlorthalidone Generic | 31 | 73 | Under 11 | $504 |
| Allopurinol Generic | 21 | 56 | Under 11 | $238 |
| Thiola Ec Tiopronin | 16 | 24 | Under 11 | $178K |
| Butorphanol Tartrate Generic | 15 | 15 | Under 11 | $8,920 |
| Furosemide Generic | 13 | 15 | Under 11 | $26.29 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 13 | 13 | Under 11 | $809 |
| Potassium Chloride Generic | 13 | 30 | Under 11 | $282 |
| Lisinopril Generic | 11 | 31 | Under 11 | $172 |
| Thiola Tiopronin | 11 | 11 | Under 11 | $139K |
Brand drugs: - claims; generic drugs: 428 claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David S Goldfarb $6,393 ($6,393 in general payments such as food, travel and fees) from 1 company. The largest payer was Novo Nordisk Inc with $6,393.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 6 | $6,393 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.